In a week that started with U.S. President Donald Trump kicking off a trade war and whipping up market volatility ...
Global stocks steadied on Friday ahead of key U.S. payrolls data, with investors cautiously optimistic that the world might avoid a full-on trade war, while the ...
Donald Trump 's renewed push to take control of Greenland is setting off a high-stakes showdown with Denmark, a small country ...
The drugmaker's shares were up nearly 5% at $882 in afternoon trading. The stock has more than doubled in value in the last two years, making it the most valuable healthcare company in the world, but ...
Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...
Eli Lilly has today forecast annual profit largely above Wall Street estimates, providing some relief to investors after ...
The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...
We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...
European shares saw a rise driven by healthcare giants GSK and Novo Nordisk following robust quarterly results. Novo Nordisk's strong profits from its drug Wegovy and GSK's share buyback plan boosted ...
Novo Nordisk (NVO), the maker of the popular GLP-1 medications Wegovy and Ozempic, said potential tariffs on Europe imposed ...
Follow along for live updates on stocks, bonds and markets, including the Dow Jones Industrial Average, S&P 500 and Nasdaq Composite.